Erratum to: Interaction of Paroxetine with Mitochondrial Proteins Mediates Neuroprotection (Neurotherapeutics, (2015), 12, (200-216), DOI 10.1007/s13311-014-0315-9);Interaction of Paroxetine with Mitochondrial Proteins Mediates Neuroprotection

Neurotherapeutics

Volumn 12, Issue 1, 2015, Pages 200-216

  Steiner, Joseph P ^a,b   Bachani, Muznabanu ^b   Wolfson Stofko, Brett ^a   Lee, Myoung Hwa ^b   Wang, Tonguang ^b   Li, Guanhan ^b   Li, Wenxue ^b   Strayer, David ^c   Haughey, Norman J ^a   Nath, Avindra ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

HAND; Mitochondria; Neuroprotective; Paroxetine; SSRI

Indexed keywords

MITOCHONDRIAL PROTEIN; NEUROPROTECTIVE AGENT; PAROXETINE;

ANIMAL; CELL CULTURE; DRUG EFFECTS; HIV ASSOCIATED DEMENTIA; HUMAN; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; METABOLISM; MOUSE; RAT; SPRAGUE DAWLEY RAT; TUNEL ASSAY; WESTERN BLOTTING;

AIDS DEMENTIA COMPLEX; ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MICE; MICE, KNOCKOUT; MITOCHONDRIAL PROTEINS; NEUROPROTECTIVE AGENTS; PAROXETINE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84940000608     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-015-0406-2     Document Type: Erratum

References (64)

1. Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, Leblanc S, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol. 2011;17(1):3–16. Epub 2010/12/22.
2. McArthur JC, Steiner J, Sacktor N, Nath A. Human immunodeficiency virus-associated neurocognitive disorders: Mind the gap. Annals of neurology. 2010;67(6):699–714. Epub 2010/06/03.
3. Badiee J, Moore DJ, Atkinson JH, Vaida F, Gerard M, Duarte NA, et al. Lifetime suicidal ideation and attempt are common among HIV + individuals. J Affect Disord. 2012;136(3):993–9. Epub 2011/07/26.
4. Eller LS, Bunch EH, Wantland DJ, Portillo CJ, Reynolds NR, Nokes KM, et al. Prevalence, correlates, and self-management of HIV-related depressive symptoms. AIDS Care. 2010;22(9):1159–70. Epub 2010/09/09.
5. Ciesla JA, Roberts JE. Meta-analysis of the relationship between HIV infection and risk for depressive disorders. Am J Psychiatry. 2001;158(5):725–30.
6. Levine AJ, Singer EJ, Sinsheimer JS, Hinkin CH, Papp J, Dandekar S, et al. CCL3 genotype and current depression increase risk of HIV-associated dementia. Neurobehav HIV Med. 2009;1:1–7. Epub 2010/08/21.
7. Wolkowitz OM, Mellon SH, Epel ES, Lin J, Dhabhar FS, Su Y, et al. Leukocyte telomere length in major depression: correlations with chronicity, inflammation and oxidative stress--preliminary findings. PLoS One. 2011;6(3):e17837. Epub 2011/03/31
8. Schifitto G, Navia BA, Yiannoutsos CT, Marra CM, Chang L, Ernst T, et al. Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. Aids. 2007;21(14):1877–86.
9. Turchan J, Sacktor N, Wojna V, Conant K, Nath A. Neuroprotective therapy for HIV dementia. Curr HIV Res. 2003;1(4):373–83.
10. Kaul M. HIV's double strike at the brain: neuronal toxicity and compromised neurogenesis. Front Biosci. 2008;13:2484–94. Epub 2007/11/06.
11. Schwartz L, Civitello L, Dunn-Pirio A, Ryschkewitsch S, Berry E, Cavert W, et al. Evidence of human immunodeficiency virus type 1 infection of nestin-positive neural progenitors in archival pediatric brain tissue. J Neurovirol. 2007;13(3):274–83. Epub 2007/07/07.
12. Lee MH, Wang T, Jang MH, Steiner J, Haughey N, Ming GL, et al. Rescue of adult hippocampal neurogenesis in a mouse model of HIV neurologic disease. Neurobiology of disease. 2011;41(3):678–87. Epub 2010/12/15.
13. Mishra M, Taneja M, Malik S, Khalique H, Seth P. Human immunodeficiency virus type 1 Tat modulates proliferation and differentiation of human neural precursor cells: implication in NeuroAIDS. J Neurovirol. 2010;16(5):355–67. Epub 2010/09/16.
14. Okamoto S, Kang YJ, Brechtel CW, Siviglia E, Russo R, Clemente A, et al. HIV/gp120 decreases adult neural progenitor cell proliferation via checkpoint kinase-mediated cell-cycle withdrawal and G1 arrest. Cell Stem Cell. 2007;1(2):230–6.
15. Hollman AM, Christian DA, Ray PD, Galey D, Turchan J, Nath A, et al. Selective isolation and purification of tat protein via affinity membrane separation. Biotechnology progress. 2005;21(2):451–9. Epub 2005/04/02.
16. Wang T, Lee MH, Choi E, Pardo-Villamizar CA, Lee SB, Yang IH, et al. Granzyme B-induced neurotoxicity is mediated via activation of PAR-1 receptor and Kv1.3 channel. PLoS One. 2012;7(8):e43950. Epub 2012/09/07.
17. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of immunological methods. 1983;65(1–2):55–63. Epub 1983/12/16.
18. Louboutin JP, Agrawal L, Reyes BA, Van Bockstaele EJ, Strayer DS. A rat model of human immunodeficiency virus 1 encephalopathy using envelope glycoprotein gp120 expression delivered by SV40 vectors. J Neuropathol Exp Neurol. 2009;68(5):456–73. Epub 2009/06/16.
19. Toggas SM, Masliah E, Rockenstein EM, Rall GF, Abraham CR, Mucke L. Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. Nature. 1994;367(6459):188–93. Epub 1994/01/13.
20. Lie DC, Colamarino SA, Song HJ, Desire L, Mira H, Consiglio A, et al. Wnt signalling regulates adult hippocampal neurogenesis. Nature. 2005;437(7063):1370–5. Epub 2005/10/28.
21. Friberg H, Connern C, Halestrap AP, Wieloch T. Differences in the activation of the mitochondrial permeability transition among brain regions in the rat correlate with selective vulnerability. J Neurochem. 1999;72(6):2488–97. Epub 1999/06/01.
22. Haughey NJ, Mattson MP. Calcium dysregulation and neuronal apoptosis by the HIV-1 proteins Tat and gp120. J Acquir Immune Defic Syndr. 2002;31 Suppl 2:S55-61. Epub 2002/10/24.
23. Mattson MP, Haughey NJ, Nath A. Cell death in HIV dementia. Cell Death Differ. 2005;12 Suppl 1:893–904. Epub 2005/03/12.
24. Sacktor N, Haughey N, Cutler R, Tamara A, Turchan J, Pardo C, et al. Novel markers of oxidative stress in actively progressive HIV dementia. J Neuroimmunol. 2004;157(1–2):176–84.
25. Nath S, Bachani M, Harshavardhana D, Steiner JP. Catechins protect neurons against mitochondrial toxins and HIV proteins via activation of the BDNF pathway. Journal of neurovirology. 2012;18(6):445–55. Epub 2012/08/14.
26. Li W, Galey D, Mattson MP, Nath A. Molecular and cellular mechanisms of neuronal cell death in HIV dementia. Neurotox Res. 2005;8(1–2):119–34. Epub 2005/11/02.
27. Nath A, Haughey NJ, Jones M, Anderson C, Bell JE, Geiger JD. Synergistic neurotoxicity by human immunodeficiency virus proteins Tat and gp120: protection by memantine. Ann Neurol. 2000;47(2):186–94.
28. Conant K, Garzino-Demo A, Nath A, McArthur JC, Halliday W, Power C, et al. Induction of monocyte chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and elevation in AIDS dementia. Proceedings of the National Academy of Sciences of the United States of America. 1998;95(6):3117–21. Epub 1998/04/18.
29. Sawaya BE, Thatikunta P, Denisova L, Brady J, Khalili K, Amini S. Regulation of TNFalpha and TGFbeta-1 gene transcription by HIV-1 Tat in CNS cells. Journal of neuroimmunology. 1998;87(1–2):33–42. Epub 1998/07/22.
30. McManus CM, Weidenheim K, Woodman SE, Nunez J, Hesselgesser J, Nath A, et al. Chemokine and chemokine-receptor expression in human glial elements: induction by the HIV protein, Tat, and chemokine autoregulation. The American journal of pathology. 2000;156(4):1441–53. Epub 2000/04/07.
31. Pu H, Tian J, Flora G, Lee YW, Nath A, Hennig B, et al. HIV-1 Tat protein upregulates inflammatory mediators and induces monocyte invasion into the brain. Molecular and cellular neurosciences. 2003;24(1):224–37. Epub 2003/10/11.
32. Nicholls DG. Mitochondrial calcium function and dysfunction in the central nervous system. Biochim Biophys Acta. 2009;1787(11):1416–24. Epub 2009/03/21.
33. Fitting S, Xu R, Bull C, Buch SK, El-Hage N, Nath A, et al. Interactive comorbidity between opioid drug abuse and HIV-1 Tat: chronic exposure augments spine loss and sublethal dendritic pathology in striatal neurons. The American journal of pathology. 2010;177(3):1397–410. Epub 2010/07/24.
34. Hyttel J. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol. 1994;9 Suppl 1:19–26. Epub 1994/03/01.
35. Preskorn SH. Dose-effect and concentration-effect relationships with new antidepressants. Psychopharmacol Ser. 1993;10:174–89.
36. Zisook S, Peterkin J, Goggin KJ, Sledge P, Atkinson JH, Grant I. Treatment of major depression in HIV-seropositive men. HIV Neurobehavioral Research Center Group. J Clin Psychiatry. 1998;59(5):217–24.
37. Rabkin JG, Wagner GJ, Rabkin R. Fluoxetine treatment for depression in patients with HIV and AIDS: a randomized, placebo-controlled trial. Am J Psychiatry. 1999;156(1):101–7.
38. Schwartz JA, McDaniel JS. Double-blind comparison of fluoxetine and desipramine in the treatment of depressed women with advanced HIV disease: a pilot study. Depress Anxiety. 1999;9(2):70–4.
39. Malberg JE, Eisch AJ, Nestler EJ, Duman RS. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci. 2000;20(24):9104–10. Epub 2000/01/11.
40. Boldrini M, Underwood MD, Hen R, Rosoklija GB, Dwork AJ, John Mann J, et al. Antidepressants increase neural progenitor cells in the human hippocampus. Neuropsychopharmacology. 2009;34(11):2376–89. Epub 2009/07/17.
41. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science. 2003;301(5634):805–9. Epub 2003/08/09.
42. Surget A, Saxe M, Leman S, Ibarguen-Vargas Y, Chalon S, Griebel G, et al. Drug-dependent requirement of hippocampal neurogenesis in a model of depression and of antidepressant reversal. Biol Psychiatry. 2008;64(4):293–301. Epub 2008/04/15.
43. Bolo NR, Hode Y, Nedelec JF, Laine E, Wagner G, Macher JP. Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. Neuropsychopharmacology. 2000;23(4):428–38. Epub 2000/09/16.
44. Henry ME, Schmidt ME, Hennen J, Villafuerte RA, Butman ML, Tran P, et al. A comparison of brain and serum pharmacokinetics of R-fluoxetine and racemic fluoxetine: A 19-F MRS study. Neuropsychopharmacology. 2005;30(8):1576–83. Epub 2005/05/12.
45. Adamson DC, Wildemann B, Sasaki M, Glass JD, McArthur JC, Christov VI, et al. Immunologic NO synthase: elevation in severe AIDS dementia and induction by HIV-1 gp41. Science. 1996;274(5294):1917–21. Epub 1996/12/13.
46. Zhao ML, Kim MO, Morgello S, Lee SC. Expression of inducible nitric oxide synthase, interleukin-1 and caspase-1 in HIV-1 encephalitis. J Neuroimmunol. 2001;115(1–2):182–91. Epub 2001/04/03.
47. Li W, Malpica-Llanos TM, Gundry R, Cotter RJ, Sacktor N, McArthur J, et al. Nitrosative stress with HIV dementia causes decreased L-prostaglandin D synthase activity. Neurology. 2008;70(19 Pt 2):1753–62. Epub 2007/12/14.
48. Liu X, Jana M, Dasgupta S, Koka S, He J, Wood C, et al. Human immunodeficiency virus type 1 (HIV-1) tat induces nitric-oxide synthase in human astroglia. J Biol Chem. 2002;277(42):39312–9. Epub 2002/08/09.
49. Eden A, Price RW, Spudich S, Fuchs D, Hagberg L, Gisslen M. Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy. The Journal of infectious diseases. 2007;196(12):1779–83. Epub 2008/01/15.
50. Nisoli E, Clementi E, Paolucci C, Cozzi V, Tonello C, Sciorati C, et al. Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide. Science. 2003;299(5608):896–9. Epub 2003/02/08.
51. Chen K, Northington FJ, Martin LJ. Inducible nitric oxide synthase is present in motor neuron mitochondria and Schwann cells and contributes to disease mechanisms in ALS mice. Brain Struct Funct. 2010;214(2–3):219–34. Epub 2009/11/06.
52. Venkatraman A, Shiva S, Wigley A, Ulasova E, Chhieng D, Bailey SM, et al. The role of iNOS in alcohol-dependent hepatotoxicity and mitochondrial dysfunction in mice. Hepatology. 2004;40(3):565–73. Epub 2004/09/07.
53. Maertens C, Droogmans G, Verbesselt R, Nilius B. Block of volume-regulated anion channels by selective serotonin reuptake inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 2002;366(2):158–65.
54. Hisadome K, Koyama T, Kimura C, Droogmans G, Ito Y, Oike M. Volume-regulated anion channels serve as an auto/paracrine nucleotide release pathway in aortic endothelial cells. J Gen Physiol. 2002;119(6):511–20.
55. Yeung SY, Millar JA, Mathie A. Inhibition of neuronal KV potassium currents by the antidepressant drug, fluoxetine. Br J Pharmacol. 1999;128(7):1609–15.
56. Choi JS, Hahn SJ, Rhie DJ, Yoon SH, Jo YH, Kim MS. Mechanism of fluoxetine block of cloned voltage-activated potassium channel Kv1.3. J Pharmacol Exp Ther. 1999;291(1):1–6.
57. Choi BH, Choi JS, Ahn HS, Kim MJ, Rhie DJ, Yoon SH, et al. Fluoxetine blocks cloned neuronal A-type K + channels Kv1.4. Neuroreport. 2003;14(18):2451–5.
58. Perchenet L, Hilfiger L, Mizrahi J, Clement-Chomienne O. Effects of anorexinogen agents on cloned voltage-gated K(+) channel hKv1.5. J Pharmacol Exp Ther. 2001;298(3):1108–19.
59. Kobayashi T, Washiyama K, Ikeda K. Inhibition of G protein-activated inwardly rectifying K + channels by fluoxetine (Prozac). Br J Pharmacol. 2003;138(6):1119–28.
60. Thomas D, Gut B, Wendt-Nordahl G, Kiehn J. The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (HERG) potassium channels. J Pharmacol Exp Ther. 2002;300(2):543–8.
61. Nahon E, Israelson A, Abu-Hamad S, Varda SB. Fluoxetine (Prozac) interaction with the mitochondrial voltage-dependent anion channel and protection against apoptotic cell death. FEBS Lett. 2005;579(22):5105–10.
62. Thinnes FP. Does fluoxetine (Prozak) block mitochondrial permeability transition by blocking VDAC as part of permeability transition pores? Mol Genet Metab. 2005;84(4):378.
63. Halestrap AP, Brenner C. The adenine nucleotide translocase: a central component of the mitochondrial permeability transition pore and key player in cell death. Curr Med Chem. 2003;10(16):1507–25. Epub 2003/07/23.
64. Friberg H, Ferrand-Drake M, Bengtsson F, Halestrap AP, Wieloch T. Cyclosporin A, but not FK 506, protects mitochondria and neurons against hypoglycemic damage and implicates the mitochondrial permeability transition in cell death. J Neurosci. 1998;18(14):5151–9. Epub 1998/07/03.